Effect of 5-Campestenone (24-methylcholest-5-en-3-one) on Zucker Diabetic Fatty Rats as a Type 2 Diabetes Mellitus Model

Abstract

We examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one), an enone derivative of campesterol, in Zucker diabetic fatty (ZDF) rats, an animal model of type 2 diabetes mellitus. Dietary 0.6 % exposure to 5-campestenone caused marked reduction in hemoglobin A1c (HbA1c), plasma total cholesterol, triglycerides and non esterified fatty acid (NEFA). In particular, plasma triglyceride levels were reduced in the 0.6 % 5-campestenone-fed group to about 25 % of that in the control group. In the oral glucose tolerance test (OGTT) at three and seven weeks after the beginning of treatment, 5-campestenone limited the rise of blood glucose levels by oral administration of glucose dose-dependently. Amounts of adipose tissue in the retroperitoneum and periepididymal area as well as abdominal subcutaneous fat were significantly decreased in animals fed 0.6 % 5-campestenone. The blood leptin concentration on the final day of feeding was significantly in animals administered 5-campestenone. No obvious anomaly due to consumption of 5-campestenone was detected in necropsy or clinical observations.

Key words

5-campestenone · Zucker diabetic fatty rat · Body fat (adipose tissue) · Plasma non-esterified fatty acid · Plasma triglyceride

References

• 1 Lee Y, Hirose H, Ohneda M, Johnson J H, MacGarry J D. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell-relationships.  Proc Natl Acad Sci USA. 1994;  91 10 878-10 882
• 2 Randle P J, Arland P B, Hales C N, Newsholme E A. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.  Lancet. 1963;  1 785-789
• 3 Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.  Diabetes. 1997;  46 3-10
• 4 Suzuki K. Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol, on mice.  J Nutr Sci Vitaminol. 1993;  39 537-543
• 5 Suzuki K, Shimizu T, Nakata T. The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.  Bioorg Med Chem Lett. 1998;  8 2133-2138
• 6 Suzuki K, Tanaka M, Konno R, Kaneko Y. Effect of 5-Campestenone (24-Methylcholest-5-en-3-one) on the Type 2 Diabetes Mellitus Model Animal C57BL/Ksj-db/db Mice.  Horm Metab Res. 2002;  34 121-126
• 7 Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakano K. Molecular cloning of rat leptin receptor isoform complementary DNAs: identification of a missense mutation in Zucker fatty (fa/fa) rats.  Biochem Biophys Res Commun. 1996;  5, 225 (1) 75-83
• 8 Parish E J, Luo C, Parish S, Heideprien R W. Selective oxidation of steroidal homoallylic alcohols using pyridium chlorochromate (PPC).  Synthetic Communications. 1992;  22 2839-2847
• 9 Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity.  Metabolism. 1987;  36 (1) 54-59
• 10 Norman M, Kaplan M D. Deadly Quartet.  Arch Intern Med. 1989;  149 1514-1520
• 11 Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arznein-Forsch/Drug.  Res. 1990;  40 (1) 156-162
• 12 Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.  Arznein-Forsch/Drug Res. 1990;  40 (1) 263-267